ARIA Care Pathways 2019: Next-Generation Allergic Rhinitis Care and Allergen Immunotherapy in Malaysia
暂无分享,去创建一个
C. Bachert | A. Bedbrook | B. Abdullah | W. Czarlewski | S. Husain | A. H. Abdul Latiff | J. Bousquet | Y. Yap | Vincent Tan | K. Woo | Palaniappan Suppiah | Tang Ing Ping | Holger J. Schunemann | A. A. Abdul Latiff
[1] R. Pawankar,et al. Malaysian Society of Allergy and Immunology Consensus Statement on Sublingual Immunotherapy in Allergic Rhinitis , 2023, Journal of clinical medicine.
[2] S. Subha,et al. Prevalence, causes and treatments of allergic rhinitis in Malaysia: a literature review , 2022, The Egyptian Journal of Otolaryngology.
[3] B. Abdullah,et al. Medication Adherence to Intranasal Corticosteroids in Allergic Rhinitis Patients with Comorbid Medical Conditions , 2022, Pharmaceutics.
[4] B. Abdullah,et al. Reshaping the Management of Allergic Rhinitis in Primary Care: Lessons from the COVID-19 Pandemic , 2022, International journal of environmental research and public health.
[5] R. Mösges,et al. Pharmacological Management of Allergic Rhinitis: A Consensus Statement from the Malaysian Society of Allergy and Immunology , 2022, Journal of asthma and allergy.
[6] R. Metson,et al. Endoscopic sinus surgery for chronic rhinosinusitis: 22‐item Sino‐Nasal Outcome Test 5‐year results , 2021, International forum of allergy & rhinology.
[7] B. Abdullah,et al. Surgical Interventions for Inferior Turbinate Hypertrophy: A Comprehensive Review of Current Techniques and Technologies , 2021, International journal of environmental research and public health.
[8] O. Pfaar,et al. Anti-IgE: A treatment option in allergic rhinitis? , 2021, Allergologie select.
[9] S. Chua,et al. The extent and barriers in providing pharmaceutical care services by community pharmacists in Malaysia: a cross-sectional study , 2020, BMC Health Services Research.
[10] D. Wang,et al. Primary care management of allergic rhinitis: a cross-sectional study in four ASEAN countries , 2020, Multidisciplinary respiratory medicine.
[11] A. Sheikh,et al. Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases , 2019, Clinical and Translational Allergy.
[12] Airways ICPs initiative,et al. ARIA pharmacy 2018 “Allergic rhinitis care pathways for community pharmacy”: AIRWAYS ICPs initiative (European Innovation Partnership on Active and Healthy Ageing, DG CONNECT and DG Santé) POLLAR (Impact of Air POLLution on Asthma and Rhinitis) GARD Demonstration project , 2019 .
[13] A. Sheikh,et al. Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study. , 2019, The Journal of allergy and clinical immunology.
[14] C. Pitsios,et al. Ways to increase adherence to allergen immunotherapy , 2019, Current medical research and opinion.
[15] A. Sheikh,et al. 2019 ARIA Care pathways for allergen immunotherapy , 2019, Allergy.
[16] J. Bousquet,et al. Vilnius Declaration on chronic respiratory diseases: multisectoral care pathways embedding guided self-management, mHealth and air pollution in chronic respiratory diseases , 2019, Clinical and Translational Allergy.
[17] D. Price,et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. , 2019, The Journal of allergy and clinical immunology.
[18] Todor A Popov,et al. ARIA pharmacy 2018 “Allergic rhinitis care pathways for community pharmacy” , 2019, Allergy.
[19] Rosalind W. Picard,et al. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence , 2018, Clinical and Translational Allergy.
[20] Y. Okamoto,et al. Efficacy and safety of SQ house dust mite sublingual immunotherapy‐tablet in Japanese children , 2018, Allergy.
[21] Daniel Laune,et al. POLLAR: Impact of air POLLution on Asthma and Rhinitis; a European Institute of Innovation and Technology Health (EIT Health) project , 2018, Clinical and Translational Allergy.
[22] A. Sheikh,et al. Treatment of allergic rhinitis using mobile technology with real‐world data: The MASK observational pilot study , 2018, Allergy.
[23] S. Durham,et al. Duration of Allergen Immunotherapy for Long-Term Efficacy in Allergic Rhinoconjunctivitis , 2018, Current Treatment Options in Allergy.
[24] Boleslaw Samolinski,et al. Electronic Clinical Decision Support System for allergic rhinitis management: MASK e‐CDSS , 2018, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[25] A. Sheikh,et al. Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the MASK study , 2018, Allergy.
[26] C. Janson,et al. Having concomitant asthma phenotypes is common and independently relates to poor lung function in NHANES 2007–2012 , 2018, Clinical and Translational Allergy.
[27] A. Sheikh,et al. EAACI guidelines on allergen immunotherapy: Executive statement , 2018, Allergy.
[28] A. Sheikh,et al. Challenges in the implementation of the EAACI AIT guidelines: A situational analysis of current provision of allergen immunotherapy , 2018, Allergy.
[29] A. Sheikh,et al. EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis , 2018, Allergy.
[30] A. Sheikh,et al. The Allergic Rhinitis and its Impact on Asthma (ARIA) score of allergic rhinitis using mobile technology correlates with quality of life: The MASK study , 2018, Allergy.
[31] A. Sheikh,et al. Allergen manufacturing and quality aspects for allergen immunotherapy in Europe and the United States: An analysis from the EAACI AIT Guidelines Project , 2018, Allergy.
[32] P. Devillier,et al. Sublingual immunotherapy provides long‐term relief in allergic rhinitis and reduces the risk of asthma: A retrospective, real‐world database analysis , 2017, Allergy.
[33] E. Valovirta,et al. Results from the 5‐year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy , 2017, The Journal of allergy and clinical immunology.
[34] E. Meltzer,et al. Treatment of seasonal allergic rhinitis: An evidence-based focused 2017 guideline update. , 2017, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[35] G. Canonica,et al. Evidence of the efficacy and safety of house dust mite subcutaneous immunotherapy in elderly allergic rhinitis patients: a randomized, double-blind placebo-controlled trial , 2017, Clinical and Translational Allergy.
[36] A. Sheikh,et al. EAACI guidelines on allergen immunotherapy: Prevention of allergy , 2017, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.
[37] Joaquim Mullol,et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision , 2017, The Journal of allergy and clinical immunology.
[38] J. Bousquet,et al. Multi-morbidities of allergic rhinitis in adults: European Academy of Allergy and Clinical Immunology Task Force Report , 2017, Clinical and Translational Allergy.
[39] A. Sheikh,et al. Allergen immunotherapy for the prevention of allergy: A systematic review and meta‐analysis , 2017, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.
[40] Todor A Popov,et al. ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle , 2016, Clinical and Translational Allergy.
[41] Todor A Popov,et al. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. , 2016, The Journal of allergy and clinical immunology.
[42] S. Sararaks,et al. Improving Health Care Coverage, Equity, And Financial Protection Through A Hybrid System: Malaysia's Experience. , 2016, Health affairs.
[43] M. Woodward,et al. Mobile Telephone Text Messaging for Medication Adherence in Chronic Disease: A Meta-analysis. , 2016, JAMA internal medicine.
[44] R. Lockey,et al. Solving the Problem of Nonadherence to Immunotherapy. , 2016, Immunology and allergy clinics of North America.
[45] J. Bousquet,et al. Allergen Immunotherapy (AIT): a prototype of Precision Medicine , 2015, The World Allergy Organization journal.
[46] F. Rodenas,et al. MACVIA‐ARIA Sentinel NetworK for allergic rhinitis (MASK‐rhinitis): the new generation guideline implementation , 2015, Allergy.
[47] J. Romualdez,et al. Attitudes, practices on allergic rhinitis of generalists and specialists in Philippine National Capital Region , 2015, Asia Pacific allergy.
[48] M. Illario,et al. Self-Assessment of Adherence to Medication: A Case Study in Campania Region Community-Dwelling Population , 2015, Journal of aging research.
[49] P. Demoly,et al. Clinical contraindications to allergen immunotherapy: an EAACI position paper , 2015, Allergy.
[50] Shu-chuen Li,et al. Quality use of medicine in a developing economy: Measures to overcome challenges in the Malaysian healthcare system , 2015, SAGE open medicine.
[51] R. Naidu,et al. Clinical manifestation and sensitization of allergic children from Malaysia , 2015, Asia Pacific allergy.
[52] J. Bousquet,et al. MASK-rhinitis, a single tool for integrated care pathways in allergic rhinitis. , 2015, World hospitals and health services : the official journal of the International Hospital Federation.
[53] H. Sitter,et al. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases , 2014, Allergo Journal International.
[54] M. Blaiss,et al. Current Allergic Rhinitis Experiences Survey (CARES): Health-care practitioners' awareness, attitudes and practices. , 2014, Allergy and asthma proceedings.
[55] D. Postma,et al. Integrated care pathways for airway diseases (AIRWAYS-ICPs) , 2014, European Respiratory Journal.
[56] J. Bousquet,et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. , 2014, Allergy.
[57] J. Bousquet,et al. Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. , 2013, The Journal of allergy and clinical immunology.
[58] L. Falzon,et al. Treatments for Seasonal Allergic Rhinitis , 2013 .
[59] J. Bousquet,et al. Uncontrolled allergic rhinitis and chronic rhinosinusitis: where do we stand today? , 2013, Allergy.
[60] M. Blaiss,et al. Asthma burden in the United States: results of the 2009 Asthma Insight and Management survey. , 2012, Allergy and asthma proceedings.
[61] Holger J Schünemann,et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. , 2010, The Journal of allergy and clinical immunology.
[62] H. Iro,et al. Septoplasty outcome in patients with and without allergic rhinitis. , 2009, Rhinology.
[63] G. Viegi,et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 * , 2008, Allergy.
[64] Erkka Valovirta,et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). , 2002, The Journal of allergy and clinical immunology.
[65] S. Chesrown,et al. Adherence to Oral Montelukast and Inhaled Fluticasone in Children with Persistent Asthma , 2001, Pharmacotherapy.
[66] A. Razak,et al. Prevalence of asthma, rhinitis and eczema among schoolchildren in Kelantan, Malaysia , 1997, Acta paediatrica Japonica : Overseas edition.